Since Tuesday, the European Medicines Agency (EMA) examines the application for marketing authorization for the vaccine developed by the University of Oxford and the AstraZeneca laboratory.
This British product is cheaper than its RNA competitors from Pfizer / BioNTech and Moderna because its technology is less complex.
It uses a chimpanzee adenovirus rendered harmless and used as a vector for the gene inducing the production of the spike protein, typical of Sars-CoV-2.
As for the two anti-Covid vaccines already endorsed by the agency, AstraZeneca began in October to communicate to the agency the first results.
Enough to allow the EMA to deliver its verdict in an accelerated manner on January 29, and the High Authority for Health (HAS) to position it in the French vaccine strategy in the wake.
Although a green light is expected for this third vaccine candidate, already authorized in the UK and India, questions about its effectiveness still arise.
Read also:
Covid-19: why vaccines definitely limit contagiousness
Out of the four clinical tests
This article is for subscribers only.
You have 75% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in
